VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Viewpoints: Political stand-off on insurance industry safeguards; VA's problems may lie in how government works

The Obama administration calls it an adjustment, Republicans call it a bailout and insurance companies call it the one thing that might keep them from raising rates and angering policyholders.

28 May 2014

New drug approach for safer clean-up of deformed blood vessels in eye

A new drug approach has been developed for safer clean-up of deformed blood vessels in the eye by a research team at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital in Toronto.

12 May 2014

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Clovis Oncology, Inc. reported financial results for its first quarter ended March 31, 2014, and provided an update on the Company's clinical development programs for the rest of 2014.

9 May 2014

Monthly injections to counteract AMD may not be necessary, say researchers

Researchers have found that, contrary to prvious clinical trial findings, monthly injections to counteract age-related macular degeneration (AMD) may not be necessary.

7 May 2014

New research suggests that Kindlin-3 regulates 2 major hallmarks of breast cancer

A protein believed to be limited to the hematopoietic system, called Kindlin-3, has been identified as a major player in both the formation and spread of breast cancer to other organs.

2 May 2014

Genetic biomarkers of ranibizumab response remain elusive in Koreans with AMD

Researchers have failed to find a significant genotypic effect on ranibizumab treatment response in Korean patients with neovascular age-related macular degeneration.

1 May 2014

Ranibizumab trial gets promising results for CNV

Patients with visual impairment due to myopic choroidal neovascularisation achieve better visual acuity after 3 months of individualised treatment with ranibizumab than with verteporfin photodynamic therapy, show the results of a phase III randomised controlled trial.

1 May 2014

FDA approves Cyramza to treat patients with advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

Multiple lines of targeted therapy extend life for mRCC patients

Overall survival of patients with metastatic renal cell carcinoma is extended the more lines of targeted therapy they receive, shows an evaluation of a large retrospective multicentre database.

22 Apr 2014

Scientists examine Gpr109a receptor to find potential treatment for diabetic retinopathy

Like a daily pill to lower cholesterol can reduce heart attack and stroke risk, an easy-to-use agent that reduces eye inflammation could help save the vision of diabetics, scientists say.

22 Apr 2014

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics, Inc., a biotechnology company focused on developing therapeutics for serious eye disorders, announced today that it has successfully completed a $20 million Series B-1 equity financing from new investors MPM Capital, Lundbeckfond Ventures, and H.I.G. BioVentures.

16 Apr 2014

BIDMC scientist wins Gairdner Award for landmark discovery in the field of angiogenesis

Harold F. Dvorak, MD, senior investigator in the Center for Vascular Biology Research at Beth Israel Deaconess Medical Center and former chairman of BIDMC's Department of Pathology, is one of eight scientists to win the 2014 Canada Gairdner Awards, which recognize some of the most significant medical discoveries from around the world. Awarded by the Gairdner Foundation, based in Canada, the awards are considered among the most prestigious international awards in medical research.

29 Mar 2014

Insulin-secreting beta cells of pancreas have capacity to regenerate, say scientists

Vanderbilt University scientists have found evidence that the insulin-secreting beta cells of the pancreas, which are either killed or become dysfunctional in the two main forms of diabetes, have the capacity to regenerate.

20 Mar 2014

Ocular Therapeutix starts Phase 3 clinical program to evaluate safety, efficacy of dexamethasone

Ocular Therapeutix, Inc. announces the start of its Phase 3 clinical program to evaluate the safety and efficacy of their sustained release dexamethasone, an ophthalmic corticosteroid for the treatment of post-operative inflammation and pain following cataract surgery. Ocular Therapeutix's dexamethasone is administered as a one-time, bioabsorbable intracanalicular plug for release of the steroid to the ocular surface for up 30 days.

18 Mar 2014

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Synta Pharmaceuticals Corp. and QuantumLeap Healthcare Collaborative today announced that Synta's lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).

11 Mar 2014

ThromboGenics receives IWT grant to study potential new biotherapeutics for DME

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines for the back of the eye, today announces that it has been awarded a €3 million grant from the Flemish agency for Innovation by Science and Technology.

10 Mar 2014

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted an application for marketing authorization for EYLEA (aflibercept) Injection for the treatment of patients with diabetic macular edema (DME) to the Japanese Ministry of Health, Labour and Welfare.

3 Mar 2014

Ophthotech reports net loss of $20.4 million for fourth quarter 2013

Ophthotech Corporation today announced financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on the Company's business and product development programs.

27 Feb 2014

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).

26 Feb 2014

VEGF News and Research

Further Reading

Viewpoints: Political stand-off on insurance industry safeguards; VA's problems may lie in how government works

New drug approach for safer clean-up of deformed blood vessels in eye

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Monthly injections to counteract AMD may not be necessary, say researchers

New research suggests that Kindlin-3 regulates 2 major hallmarks of breast cancer

Genetic biomarkers of ranibizumab response remain elusive in Koreans with AMD

Ranibizumab trial gets promising results for CNV

FDA approves Cyramza to treat patients with advanced stomach cancer

Multiple lines of targeted therapy extend life for mRCC patients

Scientists examine Gpr109a receptor to find potential treatment for diabetic retinopathy

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

Iconic Therapeutics completes $20 million Series B-1 equity financing

BIDMC scientist wins Gairdner Award for landmark discovery in the field of angiogenesis

Insulin-secreting beta cells of pancreas have capacity to regenerate, say scientists

Ocular Therapeutix starts Phase 3 clinical program to evaluate safety, efficacy of dexamethasone

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

ThromboGenics receives IWT grant to study potential new biotherapeutics for DME

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Ophthotech reports net loss of $20.4 million for fourth quarter 2013

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo